Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1):Results of the primary analysis

Authors :: N. Lopez Busto
Nadia Amellal
A.J. ten Tije
V. Moiseenko
Ronan Fougeray
Daniil Stroyakovskiy
G.J.M. Creemers
R. Glynne-Jones
Akira Kanehisa
A.J. van de Wouw
Per Pfeiffer
Krzysztof Lesniewski-Kmak
Guillem Argiles
Christophe Borg
E. Van Cutsem
Harpreet Wasan
Mikhail Fedyanin
Mark N. K. Saunders
C.J.A. Punt
Source :: Lesniewski-Kmak, K, Moiseenko, V, Saunders, M, Wasan, H, Argiles, G, Borg, C, Creemers, G, Fedyanin, M, Glynne-Jones, R, Pfeiffer, P, Punt, C, Stroyakovskiy, D, Ten Tije, A, Van de Wouw, A, Kanehisa, A, Fougeray, R, Busto, N L, Amellal, N & Van Cutsem, E 2018, ' Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1) : Results of the primary analysis ', Annals of Oncology, vol. 29, no. 5, pp. v108 . https://doi.org/10.1093/annonc/mdy149.021
Publication Year :: 2018

Language :: English
Database :: OpenAIRE
Journal :: Lesniewski-Kmak, K, Moiseenko, V, Saunders, M, Wasan, H, Argiles, G, Borg, C, Creemers, G, Fedyanin, M, Glynne-Jones, R, Pfeiffer, P, Punt, C, Stroyakovskiy, D, Ten Tije, A, Van de Wouw, A, Kanehisa, A, Fougeray, R, Busto, N L, Amellal, N & Van Cutsem, E 2018, ' Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1) : Results of the primary analysis ', Annals of Oncology, vol. 29, no. 5, pp. v108 . https://doi.org/10.1093/annonc/mdy149.021
Accession number :: edsair.doi.dedup.....00f095357aa720e32d11da04372f7a47

Tools